Boston Scientific Invests $1.5B in MiRus, Accelerates Buyback with $2B

Boston Scientific made a significant move in the medical device market with its $1.5 billion investment in MiRus, securing a 34% equity stake and an option to buy the SIEGEL Balloon Expandable TAVR system . This strategic acquisition is expected to bolster the company's position in the aortic stenosis market. The transaction was followed by a $2 billion accelerated share buyback, which saw Boston Scientific's stock price increase by 5.56%.

Meanwhile, Berkshire Hathaway's transition under new CEO Greg Abel has led to significant changes in the conglomerate's investment strategies. Under Abel's leadership, Berkshire Hathaway has increased its stake in Alphabet to a top-5 position, more than tripling its investment to approximately $23 billion .

In a separate development, Abel has continued Warren Buffett's practice of returning capital to shareholders, authorizing $235 million in stock buybacks during Q1 2026 .

The moves by Boston Scientific and Berkshire Hathaway reflect the ongoing shift in the market, as companies focus on both strategic investments and returning value to shareholders.